Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Ou connectez-vous avec votre réseau social favori

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

Company

AMADIX

AMADIX_logo
5
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Amadix is a biotech company developing innovative diagnostic tools in oncology to improve the diagnosis of different types of cancer through a non-invasive test.Amadix has a pipeline of tests for early diagnosis in colon, lung and pancreatic cancer.

Valladolid, Valladolid, Spain

Send a message

  • 8

    employees

Anglais

AMADIX Who are we?

Founded in 2010, Advanced Marker Discovery, S.L. (AMADIX) is a leading Spanish molecular diagnostics company focused on developing innovative diagnostic tests for early cancer detection, which impact patient survival and quality of life. The Company’s non-invasive assays tested in blood are oriented to avoid the complications and side effects of invasive procedures and to improve on the accuracy and compliance of currently marketed non-invasive tests. The company’s lead micro-RNA (miRNA)...

See more

Founded in 2010, Advanced Marker Discovery, S.L. (AMADIX) is a leading Spanish molecular diagnostics company focused on developing innovative diagnostic tests for early cancer detection, which impact patient survival and quality of life. The Company’s non-invasive assays tested in blood are oriented to avoid the complications and side effects of invasive procedures and to improve on the accuracy and compliance of currently marketed non-invasive tests. The company’s lead micro-RNA (miRNA) based gene signature test, ColoFast, for colorectal cancer (CRC) detection is currently undergoing a prospective clinical validation study and is planned to obtain CE-Mark and to be launched in 2018. The Company’s test pipeline includes blood-based tests for early detection of lung and pancreatic cancer.

  • 1

    Like

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent